This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Evaluating the efficacy and safety of Risankizumab (SKYRIZI) in Crohn's disease
Ticker(s): ABBVWho's the expert?
Institution: The lowa Clinic
- General gastroenterologist working in the Midwest at a large multi clinic practice that is independently owned.
- Sees a variety of Gl conditions including significant inflammatory bowel disease, significant liver disease, IBS, and others.
- Participated in market research surveys and interviews for many years
Interview GoalDiscussing the current standard of care and the potential of SKYRIZI (Risankizumab) in adults with moderate to severe Crohn's disease.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
